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List of Abbreviations 
 
PDT         photodynamic therapy 
PS           photosensitizer 
ROS         reactive oxygen species 
1O2                singlet oxygen  
Φ∆           singlet oxygen quantum yields 
DMA         9,10-dimethylanthracene 
TPP          tetraphenylporphyrin 
ABDA        9,10-anthracenediyl-bis(methylene)dimalonic acid 
RB           Rose Bengal 
DMSO        dimethylsulfoxide 
DMF          N,N-dimethylformamide 
PI            phototoxic index 
PBS          phosphate-buffered saline 
IC50          compound concentrations that produce 50% of cell growth inhibition  
MTT         3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 




Porphyrins, quite unique molecules, are a group of heterocyclic macrocycle organic 
compounds, composed of four modified pyrrole subunits interconnected at their α 
carbon atoms via methine bridges. With a total of 26 electrons in the conjugated 
system, the porphyrin ring is aromatic and highly hydrophobic because of the 
extended π system. Porphyrin are biologically compatible, whose metal complexes 
are both thermodynamically and kinetically stable. They can generate singlet oxygen 
and other ROS, and obtain the ability to be preferentially retained or accumulated by 
tumors [1, 2]. 
Photodynamic therapy (PDT) uses nontoxic light-sensitive compounds, becoming 
toxic upon irradiation, to kill diseased cells (Fig. 1) [3]. PDT is a non-invasive 
treatment, which combines three essential components: photosensitizer (PS), light 
source, and oxygen to generate cytotoxic singlet oxygen (1O2). Under light irradiation, 
the PS is excited from the ground state (GPS) to the singlet state (1PS*). By the 
process of intersystem crossing, 1PS* can be converted to the excited triplet state 
(3PS*) (Fig. 2) [4]. It has been demonstrated that the dominant pathway in PDT is 
Type II [5]. Within tissue, the 3PS* can transfer energy to the molecular oxygen, and 
generate reactive oxygen species (ROS), specifically singlet oxygen (1O2). Sufficient 
1O2 generation in diseased tissues results in the irreversible destruction without 





              





Fig. 2. The generation of singlet oxygen upon irradiation and the mechanism to 
cancer cells.
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destruction of tumor tissue by invoking an immune response and vascular shutdown 
of the blood vessels surrounding the diseased tissue [6, 7]. 
Porphyrin–based photosensitizers, like Talaporfin Sodium, are widely used in clinical 
PDT, showing great retention or accumulation in tumors as the result of preferential 
binding to low-density lipoproteins [8]. However, the notorious insolubility and 
aggregation of porphyrins negatively affect their cellular uptake and restrict in vivo 
activity and applications. Given these limitations, efforts have been devoted for 
developing water-soluble cationic porphyrins that can eliminate the formation of 
aggregates by increasing the electrostatic repulsion among charged functional groups 
[9]. So we focused on metalloporphyrinates substituted with platinum-based 
anticancer drugs. 
In this study, a porphyrin framework, platinum(II)-based groups, and metal ions were 
combined to produce some novel cationic porphyrinates, aiming to enhance their 








 Chapter 1  
Water-soluble metalloporphyrinates with excellent photo-induced 
anticancer activity resulting from high tumor accumulation  
 
1.1 Introduction 
Porphyrins are quite unique molecules that are highly hydrophobic because of the 
presence of an extended π system. Functionalization with charged peripheral groups 
or insertion of metals into the core could make them water-soluble [10-15], markedly 
affecting their biodistribution and in vivo efficacy [16, 17]. With an ability to generate 
singlet oxygen and other reactive oxygen species, metalloporphyrins are 
thermodynamically and kinetically stable and show great retention or accumulation in 
tumors as the result of preferential binding to low-density lipoproteins [16, 18-20]. 
Therefore, porphyrin-based photosensitizers are promising and useful agents for 
cancer treatment in photodynamic therapy (PDT). PDT is a minimally invasive 
therapy with negligible toxicity, involving three key components: a photosensitizer, a 
light source, and tissue oxygen. Combining these three components results in the 
chemical destruction of targeted tissues under light [16, 21]. High triplet state 
quantum yields and long triplet lifetimes, which generate higher singlet oxygen 
quantum yields, are essential for efficient sensitizers. Closed-shell and diamagnetic 
ions, such as Zn2+, Ga3+, and Si4+, give porphyrin complexes that possess both high 
triplet yields and long lifetimes [22-29]. For the above reasons, gallium(III) porphyrin 
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complexes have been proven to act as an effective framework for photosensitizers 
used in PDT [29-33].  
Despite their advantages, the notorious insolubility and aggregation of porphyrins in 
aqueous solutions negatively affect their cellular uptake and restrict in vivo activity 
and applications. Given these limitations, efforts have been devoted for developing 
water-soluble cationic porphyrins that can eliminate the formation of aggregates by 
increasing the electrostatic repulsion among charged functional groups [12]. 
Meanwhile, some porphyrin and platinum conjugates have been synthesized with the 
purpose of improving both hydrophilicity and antitumor activity; these complexes 
exhibited excellent efficacy in sequential PDT treatments [34-40]. Jana et al. prepared 
a series of Zn(II) porphyrin–Pt(II) C^N^N acetylide conjugates, all of which were 
effective photosensitizers for singlet oxygen generation [41]. Lau et al. reported a 
novel Zn(II) phthalocyanine appended with oxaliplatin. The two components worked 
in a cooperative manner, and their combination showed high photodynamic activity 
and cellular uptake and induced cell death via apoptosis [36]. Consequently, the 
system combining porphyrins and Pt-based complexes generated interesting 
synergistic treatment effects, achieving a tremendous enhancement in anticancer 
effects [34, 35, 38, 42-45]. 
In light of the potential advantages, we have focused on metalloporphyrinates 
substituted with platinum-based anticancer drugs, aiming to enhance their 
hydrophilicity, thereby enabling in vivo evaluation. We also anticipated 
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tumor-targeted effects. In this study, a porphyrin framework, platinum(II)-based 
groups, and a metal ion gallium(III) were combined to produce two new pentacationic 
porphyrinates Ga-4cisPtTPyP and Ga-4transPtTPyP. Their photophysical and 
photochemical properties were investigated, and the photodynamic activities of these 
complexes in vitro and in vivo were evaluated. The complexes were found to manifest 
highly potent anticancer activity in vitro and in vivo. 
1.2 Experimental  
1.2.1 Materials and methods 
All the reagents used were of analytical or chemically pure grade. The complex of 
4cisPtTPyP was synthesized referring to the reported methods [35, 36]. Ultraviolet 
(UV) spectra were recorded on a UV-3150 UV/Vis spectrophotometer (Shimadzu, 
Kyoto, Japan). C, H, and N analysis was carried out on a LECO CHN-900 instrument 
(LECO Corporation, St. Joseph, MI, USA). Fluorescence spectra were measured 
using a Jasco FP 6500 spectrofluorometer (Jasco, Tokyo, Japan). 1H NMR spectra 
were obtained on a JEOL JNM-ECS400 spectrometer (JEOL Ltd., Tokyo, Japan) 
using tetramethylsilane as an internal reference. The absorbance was measured at 570 
nm with a Bio-Rad model 680 microplate reader (Bio-Rad Laboratories, Hercules, 
CA, USA). Irradiation was performed using a 50-W LED light source containing 45 
red and 5 blue LEDs. Colon26, a colorectal adenocarcinoma cell line derived from 
BALB/c mice, was used (TKG 0518, Cell Resource Center for Biomedical Research, 
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Tohoku University, Japan). Sarcoma180 (CCRF S180II) was obtained from Japanese 
Cancer Research Resource Bank (Tokyo, Japan). LS180 cell line was obtained from 
American Type Culture Collection (ATCC) (Manassas, VA, USA). Female BALB/c 
mice (5 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). The 
biodistribution of Ga-4cisPtTPyP in blood and tissue was determined by measuring 
the Pt and Ga concentrations using inductively coupled plasma–atomic emission 
spectrometry (ICP-AES, ICAP-6300, Thermo Fisher Scientific, Waltham, MA, USA). 
The partition coefficients (logP values) of the complexes were measured in an 
n-octanol/water system; the combined phases were shaken by vortex for 10 min, 
centrifuged for 20 min at 10,000g, and each phase was analyzed using UV/Vis 
spectrophotometry [42, 46]. 
1.2.2 Synthesis of Ga-4cisPtTPyP and Ga-4transPtTPyP 
5,10,15,20-Tetra(4-pyridyl)-21H,23H-porphine (H2TPyP) and the gallium(III) 
complex GaTPyP were obtained according to the methods reported previously [11, 
47-49]. To synthesize Ga-4cisPtTPyP, the following method was used. Cisplatin 
(0.129 mmol, 39 mg) and silver nitrate (0.129 mmol, 22 mg) were dissolved in 2 mL 
of N,N-dimethylformamide (DMF) and stirred at room temperature for 24 h. The 
resultant turbid solution was filtered to remove white silver chloride. The light 
yellow-colored filtrate was added to a solution of GaTPyP (0.0325 mmol, 24 mg) in 
DMF (2 mL). After stirring at 50°C for 72 h, the mixture was cooled to ambient 
temperature and the product was precipitated by the addition of diethyl ether. The 
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solid was filtered and washed with water, methanol, chloroform, and diethyl ether. 
The solid was dried under vacuum to afford Ga-4cisPtTPyP in the form of a purple 
powder (43 mg, 64%). 1H NMR (400 MHz; DMSO-d6): δ 9.23 (o-pyridyl and 
β-pyrrole, m, 16H), 8.45 (m-pyridyl, d, 8H, J = 6.4 Hz), 5.08 (NH3, s, 12H), 4.56 
(NH3, s, 12H), 7.95 (CH, DMF), 2.90 (CH3, DMF), 2.74 (CH3, DMF), 3.16 (CH3, 
MeOH); Elemental analysis calcd. for C40H49Cl4N20O13Pt4Ga· DMF· 5CH3OH·2H2O: 
C 25.29, H 3.47, N 12.91; obsd. C 25.36, H 3.10, N 12.59. 
Ga-4transPtTPyP was synthesized from transplatin using the same method (38 mg, 
57%). 1H NMR (400 MHz; DMSO-d6): δ 9.24 (o-pyridyl and β-pyrrole, m, 16H), 
8.46 (m-pyridyl, d, 8H, J = 6.4 Hz), 5.02 (NH3, s, 12H), 4.52 (NH3, s, 12H), 7.95 (CH, 
DMF), 2.88 (CH3, DMF), 2.72 (CH3, DMF), 3.16 (CH3, MeOH); Elemental analysis 
calcd. for C40H49Cl4N20O13Pt4Ga·DMF·4CH3OH·H2O: C 25.31, H 3.31, N 13.20; 
obsd. C 25.63, H 3.27, N 13.29. 
1.2.3 Singlet oxygen quantum yields 
Singlet oxygen quantum yields (Φ∆) were determined by photooxidation of 
9,10-dimethylanthracene (DMA) and 9,10-anthracenediyl-bis(methylene)dimalonic 
acid (ABDA) via steady-state photolysis. Tetraphenylporphyrin (TPP) in 
dimethylsulfoxide (DMSO) (  Φ∆R  =  0.52) and Rose Bengal (RB) in aqueous 
solution were used as references [21, 50-53]. DMA solution (1.45 × 10−4 M in DMSO; 
1.5 mL) or ABDA solution (2 × 10−4 M in aqueous solution) was mixed with the 
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photosensitizer in a 1-cm quartz cuvette. The initial absorbance reading of the 
reaction mixture was taken at 401 nm or 380 nm, and the cuvette was irradiated by a 
50-W LED light. The kinetics of DMA and ABDA photooxidation were measured. 
The observed rate constants were obtained by a linear least-squares fit of the 
semilogarithmic plot of lnA0/A versus time. The singlet oxygen generated by a 
photosensitizer was calculated using the following equation: 
                              Φ∆  S =  Φ∆R 
KSIR
KRIS
                                                 (1) 
where KR and KS are the slopes of the kinetic plot of DMA and ABDA disappearance 
photosensitized by the sample and standard, respectively, and IR and IS are the total 
light intensities absorbed by the sample and standard, respectively. All measurements 
were performed in triplicate. 
1.2.4 Photobiological assays 
Colon26 (mouse colon adenocarcinoma), Sarcoma180 (mouse sarcoma), and LS180 
(human colon carcinoma) cell lines were plated in 96-well plates at a density of 5 × 
103 cells/well. The cells were incubated with different concentrations of 
Ga-4cisPtTPyP, Ga-4transPtTPyP, 4cisPtTPyP, GaTPyP, a mixture of GaTPyP and 
four equivalents of cisplatin, and cisplatin for 24 h or 48 h (DMSO = 0.4%). After this 
period, the complexes were removed by washing with phosphate-buffered saline (PBS) 
and the medium was replaced. The cells were immediately irradiated by a 50-W LED 
light or left without irradiation (in the case of dark control cells) for 30 min. The 
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plates were kept in a CO2 incubator for 48 h for further cultivation. Cell viability was 
estimated by the standard MTT assay with a microplate reader at an absorbance of 
570 nm [54, 55]. All experiments were independently replicated thrice. 
1.2.5 Cellular uptake 
To compare the uptake ability of Ga-4cisPtTPyP and 4cisPtTPyP, Colon26 cells were 
treated with 20 μM Ga-4cisPtTPyP or 4cisPtTPyP at 37°C for 2 h. After incubation, 
cells were washed twice with ice-cold PBS and resolved by 1 mL of 1 M NaOH. After 
adding 3 mL 5% HNO3, the samples were analyzed using ICP–AES. The Pt content 
of each sample was normalized for the protein level, which was determined using a 
Protein Assay Bicinchoninate Kit (Nacalai Tesque) [56].  
1.2.6 Subcellular localization 
To measure the cellular uptake of the promising agent Ga-4cisPtTPyP, Colon26 cells 
were treated with 20 μM Ga-4cisPtTPyP at 37°C for 2 h and 4 h. Then the medium 
was removed, the cells were washed with PBS solution, harvested, and centrifuged. 
The pellet was suspended in a sucrose solution and incubated with buffer A (10 mM 
Hepes pH 7.9, 10 mM KCl, 0.2 mM EDTA, 1.0 mM dithiothreitol, 0.5 mM 
phenylmethylsulfonyl fluoride) on ice for 15 minutes. After adding 5% NP-40, the 
suspension was centrifuged and the supernatant was collected to get the cytosol. The 
pellet was re-dissolved in a sucrose solution and incubated with buffer B (20 mM 
Hepes pH 7.9, 0.4 M NaCl, 2 mM EDTA, 1.0 mM dithiothreitol, 1 mM 
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phenylmethylsulfonyl fluoride) on ice and centrifuged to obtain the pure nuclear 
extract and membrane [57]. Cellular platinum levels were expressed as ng of Pt per 
million cells. 
1.2.7 Animal model  
Animal experiments were conducted in strict accordance with the Guidelines for the 
Care and Use of Laboratory Animals of Kanazawa University. The animal 
experimental protocols used were approved by the Committee on Animal 
Experimentation of Kanazawa University (Permit Number: AP-153334). Female 
BALB/c mice (5 weeks old) were purchased and the Colon26 tumor models were 
generated by subcutaneous injection of 1 × 106 cells into the right and left shoulders. 
The mice were used for photodynamic therapy and biodistribution experiments when 
the tumor volume reached approximately 100 mm3. 
1.2.8 In vivo biodistribution 
Three mice per group were administered Ga-4cisPtTPyP in doses of 8 μmol/kg body 
weight. The main tissues and blood were collected at 2, 24, and 48 h after 
administration. A 25% aqueous solution of tetramethylammonium hydroxide (TMAH) 
was added to each sample and incubated for 24 h at 60°C. After centrifugation, 0.5 
mL of supernatant was mixed with 4 mL of a solution containing 1% HNO3 and 0.01% 
Triton X-100 [58, 59]. Treated samples were analyzed by monitoring the Pt and Ga 
contents using ICP–AES. 
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1.2.9 PDT in vivo 
When the tumor sizes of five mice reached approximately 100 mm3, Ga-4cisPtTPyP 
solution (5 μmol/kg) was injected into the tail vein. The tumor in the left shoulder of 
each animal was irradiated for 30 min, which was divided into three 10 min periods 
with a 5 min break between each period, while the right shoulder tumor served as a 
control, receiving Ga-4cisPtTPyP but no light. Mice were monitored for tumor growth 
and body weight up to 14 days post PDT treatment. Tumor size was measured with a 
digital slide caliper and tumor volume was calculated as LW2/2, where L and W were 
the longer and shorter diameters, respectively.  
1.2.10 Statistical analysis 
The data are expressed as means ± standard deviations where appropriate. Analyses of 
in vitro PDT assays were performed using GraphPad Prism Software, Version 5, for 
Windows (GraphPad Software, San Diego, CA, USA). For an in vivo PDT 
experiments, differences were identified using an unpaired and paired Student’s 
two-tailed t-test respectively, and were considered statistically significant when p < 
0.05. 
 
1.3 Results and Discussion 
1.3.1 Synthesis and characterization 
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To develop the novel water-soluble metalloporphyrinate Ga-4cisPtTPyP for cancer 
therapy, a Ga(III) porphyrinate (GaTPyP) was employed owing to its relatively high 
hydrophilicity [11, 48]. Cisplatin was chosen as the cytostatic part because of its high 
therapeutic efficacy. A complex having the same structure but without gallium(III), 
4cisPtTPyP, was synthesized as a reference compound. Ga-4cisPtTPyP and 
Ga-4transPtTPyP were prepared by the synthetic route shown in Scheme 1-1 and 
were characterized by 1H NMR, UV/Vis, fluorescence spectroscopy, and elemental 
analysis. Generally, porphyrins have unique optical characteristics and exhibit a 
strong absorption Soret band around 420 nm and Q bands around 550–650 nm, all of 
which make a significant contribution to PDT. The UV/Vis spectra of Ga-4cisPtTPyP 
and Ga-4transPtTPyP exhibited a bathochromically shifted Soret band centered at 427 
nm owing to the increased average electron density of the porphyrin framework, 
which lowers the energy for electron transition, and a small number of Q bands 
typical of metalloporphyrins at 554 nm and 592 nm in DMSO (Table 1-1). Upon 
excitation at 425 nm in DMSO, these complexes showed two emission peaks at 598 
nm and 648 nm. 
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Scheme 1-1. Synthesis of Ga-4cisPtTPyP, Ga-4transPtTPyP and 4cisPtTPyP. 
 
The water solubility of potential photosensitizers is an important criterion in the field 
of PDT, markedly affecting biodistribution and efficacy [16, 17]. Therefore, the 
hydrophilicity of the novel complexes was characterized by measuring the partition 
coefficient in an n-octanol/water system. As shown in Table 1-2, Ga-4cisPtTPyP and 
Ga-4transPtTPyP displayed comparatively higher hydrophilicity than 4cisPtTPyP and 
GaTPyP, which was probably the result of the overall charge differences. The ranking 
of the overall charges of these complexes, which is opposite to that of the logP values, 
is Ga-4cisPtTPyP (5+) = Ga-4transPtTPyP (5+) > 4cisPtTPyP (4+) > GaTPyP (1+). 
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That is, an increase in the overall charge results in a decrease in logP values and an 
increase in water solubility. Therefore, the conjugation of the platinum moieties and 
the insertion of gallium(III) into the porphyrinate framework result in a more 
hydrophilic complex. 
 
Table 1-1 Absorption, fluorescence spectral data, and pKa values at room temperature. 
Complex λmax / nm (ε / 104 M-1·cm-1) λem / nm a pKa1b pKa2b 
Ga-4cisPtTPyP  427 (20.0), 554 (1.2), 592 (0.3) 598,648 5.06 8.59 
Ga-4transPtTPyP  427 (22.5), 554 (1.2), 592 (0.3) 598,648 5.18 8.56 
4cisPtTPyP 
 423 (29.8), 516 (1.8), 549 (0.7), 
 589 (0.6), 643 (0.3) 
– 5.55 9.36 
a Emission spectra were recorded upon excitation at 425 nm in DMSO. 
b pKa values of Ga-4cisPtTPyP (λex = 427 nm), Ga-4transPtTPyP (λex = 427 nm), and 
4cisPtTPyP (λex = 423 nm) were determined from variation of the ratio of the 
emission intensity at maximum vs pH (298 K). 
 
Table 1-2 The logP (n-octanol/water) values and quantum yields of singlet oxygena. 
Compound logP Φ∆a    Φ∆b 
Ga-4cisPtTPyP -2.06±0.21 0.76±0.08 0.84±0.03 
Ga-4transPtTPyP -1.91±0.20 0.69±0.09 0.80±0.01 
4cisPtTPyP -1.77±0.08 0.57±0.03 0.76±0.06 
GaTPyP 0.52±0.07 0.14±0.04 – 
          a Φ∆ in DMSO (TPP as a reference, Φ∆ = 0.52 ) 
          b Φ∆ in aqueous solution (RB as a reference, Φ∆ = 0.76 ) 
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1.3.2 Aggregation studies 
Aggregation is usually described as the coplanar association of rings progressing from 
monomer to higher order complexes [60-62]. In view of the fact that the aggregation 
state of photosensitizers is a critical factor that affects their biodistribution and 
photodynamic activities, the aggregation behaviors of Ga-4cisPtTPyP and 
Ga-4transPtTPyP were investigated in DMSO and water at different concentrations 
between 10 to 0.5 μM (Fig. 1-1). At 427 nm, both complexes obeyed the Beer–
Lambert law at the concentrations employed, which indicated that Ga-4cisPtTPyP and 
Ga-4transPtTPyP do not aggregate at these concentrations in DMSO and water. This 
is a meaningful result for Ga-4cisPtTPyP and Ga-4transPtTPyP since aggregation can 
greatly decrease the PDT effectiveness of the photosensitizer. 
1.3.3 Singlet oxygen quantum yields 
An efficient photosensitizer for application in PDT must generate singlet oxygen 
effectively because singlet oxygen is recognized as the major cytotoxic factor in this 
type of therapy [63-64]. 1O2 can react with many kinds of biological molecules such 
as DNA, proteins and lipids, causing DNA oxidation, protein oxidation and lipid 
peroxidation, respectively [65]. To evaluate the photosensitizing efficiency of the 
complexes, the photooxidation reaction of DMA and ABDA were used to estimate 
singlet oxygen production by the photosensitizers. As shown in Table 1-2, the cis 
isomer exhibited a higher level of the singlet oxygen production than that of the trans  
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Fig. 1-1. The aggregation behaviors of Ga-4cisPtTPyP and Ga-4transPtTPyP were 
investigated at different concentrations ranging from 10 μM to 0.5 μM at 427 nm: (a) 
Ga-4cisPtTPyP in DMSO; (b) Ga-4transPtTPyP in DMSO; (c) Ga-4cisPtTPyP in H2O; 
(d) Ga-4transPtTPyP in H2O.
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isomer. The Φ∆ values of Ga-4cisPtTPyP and Ga-4transPtTPyP were slightly higher 
than that of 4cisPtTPyP as a result of the heavy atom effect of gallium. A great 
improvement in singlet oxygen production by Ga-4cisPtTPyP and Ga-4transPtTPyP 
compared with GaTPyP was found following the introduction of cisplatin (from 0.14 
to 0.76) or transplatin (from 0.14 to 0.69) into the peripheral pyridine groups. The 
production of 1O2 by Pt was reported by Zhao et al. [66], who suggested a mechanism 
involving the reduction of Pt(IV) to Pt(II). The 1O2 production mechanism for our 
complexes, which were in the +2 oxidation state of platinum, might be related to a 
metal-to-ligand charge transfer mechanism [67]. Since the release of the Pt moieties 
from the porphyrinate framework (vide infra) cannot be excluded as a possible 
mechanism for 1O2 production, elucidation of the detailed mechanism requires further 
study. Overall, these complexes showed high singlet oxygen quantum yields, which 
implied that they are highly efficient singlet oxygen generators and could be applied 
in PDT.  
1.3.4 Photobiological assays 
The cytotoxicity and photocytotoxicity of the complexes were evaluated using the 
MTT assay. As shown in Table 1-3 for Colon26 and Sarcoma180 cell lines (24 h), 
Ga-4cisPtTPyP and Ga-4transPtTPyP displayed low cytotoxicity in the dark toward 
both cell lines, and the cytotoxic activities were dramatically increased upon 
illumination with a LED light. A small difference between Ga-4cisPtTPyP and 
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Ga-4transPtTPyP was observed under light and dark conditions; the cis isomer 
showed higher potential than the trans isomer, which was in agreement with the 
results of singlet oxygen quantum yields. It is noteworthy that, in the case of 
Ga-4cisPtTPyP, the ratio of IC50 values between the dark and light conditions was 
extremely large (up to ca. 1,000 in the Sarcoma180 cell line), clearly showing that this 
complex displayed the most favorable photodynamic property. These observations 
were confirmed by LS 180 cell line (Table 1-4). As a control experiment, the 
photocytotoxicity of a mixture of GaTPyP and four equivalents of cisplatin was 
determined. The anticancer effect of this mixture was significantly lower than that of 
Ga-4cisPtTPyP, proving the success of our strategy of combining the porphyrin 
framework and platinum groups. Namely, Pt-porphyrin complexes can work as 
efficient photosensitizers, for the reason that Pt atom facilitates intersystem crossing 
and improves the triplet yields and metal-to-ligand charge transfer transitions [67]. No 
significant difference was found between Ga-4cisPtTPyP and 4cisPtTPyP, suggesting 
that Ga(III) may not dramatically affect the activity when light irradiation is applied. 
On the contrary, Ga(III) could be responsible for the observed low dark cytotoxicity. 
We proposed that high hydrophilicity decreased the cellular uptake of Ga-4cisPtTPyP. 
Accordingly, the peripheral combination of platinum groups with a porphyrin 
framework, generating considerable Φ∆, makes a substantial contribution to the 
anticancer activity. It could be deduced that 1O2 is a key intermediate in the 
photodynamic action. When the cells were incubated with Ga-4cisPtTPyP for 48h,  
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              a Cancer cells were incubated for 24 h with different complexes. 
              b PI: phototoxic index. 
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IC50 was a little lower than that of 24 h, but there was no significant difference (Table 
1-5). 
 
      Table 1-4 IC50 values (μM) toward LS 180 cell lines. 
 Compound 
LS 180    PIb 
In dark With light   Dark/Light 
Ga-4cisPtTPyP 24.49±2.34 0.16±0.05  153 
4cisPtTPyP 10.48±1.83 0.17±0.04  62 
cisplatin  6.37±0.80 5.25±1.87   1.2 
         
 
         Table 1-5 IC50 values of 48 h incubation on Colon26 cell line. 
Compound 
    IC50 (μM)    PI 
In dark With light  Dark/Light 
Ga-4cisPtTPyP   > 100 0.10±0.02  > 1000 
4cisPtTPyP 6.99±1.71 0.15±0.04  47 






1.3.5 Cellular uptake 
It has been demonstrated that hydrophilic porphyrins can be internalized into cells by 
receptor-mediated endocytosis pathway, because they are too polar to diffuse across 
the cellular membrane [55]. Many key factors like molecular size, charge, and 
water-lipid partition coefficient of photosensitizers, play an important role in their 
cellular uptake and cytotoxicity. To investigate the uptake ability of Ga-4cisPtTPyP 
and 4cisPtTPyP, cellular uptake was performed on Colon26 cells (Fig. 1-2). Under the 
same condition, 4cisPtTPyP exhibited higher uptake than Ga-4cisPtTPyP with a 
significant difference. 4cisPtTPyP quickly entered the cells during 2 h incubation and 
had 7.79-fold better uptake than Ga-4cisPtTPyP. The uptake rates of Ga-4cisPtTPyP 
and 4cisPtTPyP are 0.4 μg mg-1 h-1 and 3.2 μg mg-1 h-1 respectively. Compared with 
the partition coefficients of these two complexes, Ga-4cisPtTPyP showed more 
hydrophilic, slower and lower uptake in cancer cells, explaining the negative 
cytotoxicity under dark.  
 
Fig. 1-2. Uptake following 10 μM 4cisPtTPyP and Ga-4cisPtTPyP treatment for 2 h 
on Colon26 cell line. Error bars represent standard deviations from the mean. 
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In order to further evaluate the distribution in cell fractions, a subcellular localization 
study was performed. Colon26 cells were incubated with Ga-4cisPtTPyP for 4 h, and 
the platinum content was determined in the cytosol and nucleus using ICP-AES. 
Higher level of Ga-4cisPtTPyP was detected in cytosol than in nucleus (Fig. 1-3). The 
distribution ratio of cytosol to nucleus is 1.5, whereas the ratio for 4cisPtTPyP is 
0.005 [35]. The different localization may be owing to the more acidic pKa [68], 
originating from the hydrolysis of cisplatin, in Ga-4cisPtTPyP (Table 1-1). Because of 
high oxygen concentration in cytosol, the complex located in cytosol can generate 
more singlet oxygen than in nucleus under irradiation. Otherwise, Naik et al. clarified 
that DNA is a probable main target since 4cisPtTPyP can interact with ctDNA and 
induce photocleavage after internalization into nucleus [35]. In view of the large 
portion in cytosol, we speculated that Ga-4cisPtTPyP killed cancer cells not only 
because of interaction with DNA, but also high singlet oxygen and the apoptosis 
mechanism by mitochondrial death pathways. 
 
Fig. 1-3. Cellular uptake following Ga-4cisPtTPyP treatment (20 μM for 4 h) on 
Colon26 cell line.  
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1.3.6 In vivo biodistribution  
Since Ga-4cisPtTPyP displayed excellent photocytotoxicity in vitro, the 
biodistribution of this complex in Colon26 tumor-bearing mice was evaluated using 
ICP–AES to determine the Pt and Ga concentrations in blood and major organs. From 
the results (Fig. 1-4), it was apparent that the complex experienced low uptake in the 
liver and spleen, but high uptake in the lung. It is recognized that an optimal agent 
should localize in tumor tissue with a tumor/non-tumor ratio > 3.0 [16, 69，70]. For 
this complex, the tumor/muscle Pt concentration ratio increased with time, and 
strikingly, exceeded nine-fold (from 1.05 to 9.41) at 48 h, which sufficiently 
demonstrated high accumulation in tumor cells. The preferential uptake of 
Ga-4cisPtTPyP in tumor tissue was most likely induced by binding to low-density 
lipoproteins, as it has been reported that high tumor accumulation of porphyrins is 
derived from the receptor-mediated endocytosis of low-density lipoproteins [71, 72].  
The integrity of Ga-4cisPtTPyP was evaluated by analyzing the Pt/Ga ratios in tissues 
at different time points. If the Ga-4cisPtTPyP complex remained intact in vivo, the 
ratio of Pt and Ga concentrations should theoretically be 4. However, the ratios in the 
liver, lung, and kidney were far removed from this value (Table 1-6). In the liver and 
lung, the Pt/Ga ratios decreased with time, demonstrating that Pt groups have a faster 
clearance than the Ga framework in these two organs. Pt also accumulated in the 
kidney, resulting in the Pt/Ga ratio reaching 21 at 24 h after administration. Pt was 
then excreted with the ratio dropping to 1.72 at 48 h after administration. This 
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Fig. 1-4. Pt concentration (above) and Ga concentration (below) in each tissue of 
mice at 2, 24, and 48 h after intravenous injection of Ga-4cisPtTPyP (Bld = blood; Spl 
= spleen; Pan = pancreas; Sto = stomach; L-Int = large intestine; S-Int = small 
intestine; Kid = kidney; Liv = liver; Hrt = heart; Lng = lung; Mus = muscle; Brn = 
brain; Tum = tumor).
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Table 1-6 Pt and Ga concentrations (μmol/kg) of Ga-4cisPtTPyP and distribution ratios in the liver, lung, and kidney at different time points. 
                 2h                 24h   48h 
  CPt    CGa CPt/CGa  CPt       CGa CPt/CGa   CPt CGa CPt/CGa 
Liver  99.0±4.8  49.1±7.6 2.02    58.9±0.6   32.1±13.9  1.83   112.1±6.1  127.8±18.4  0.88  
Lung 297.8±69.3 269.4±54.5 1.11   600.6±70.2  626.0±135.4 0.96   229.7±22.6  245.5±41.2  0.94  
Kidney  28.4±4.6     –a –a   21.0±2.2    1.0±1.4  21.0   31.9±7.3   18.6±5.9  1.72  
a The concentration of gallium was very low and under the limit of ICP measurement. 
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behavior could be ascribed to the fact that cisplatin is more readily accumulated in the 
renal tissue than in other tissues. From the results, we hypothesized that 
Ga-4cisPtTPyP was metabolically degraded in vivo and a few platinum groups were 
detached from the gallium framework. 
1.3.7 In vivo PDT on subcutaneous tumor-bearing mice 
The phototoxic effect of Ga-4cisPtTPyP was assessed in Colon26 tumor-bearing mice 
by monitoring the tumor volume to evaluate the therapeutic effects in vivo. To assess 
the side effects, body weight was also examined. As shown in Fig. 1-5, tumor growth 
was almost completely inhibited and remained so for two weeks after the 
Ga-4cisPtTPyP-mediated PDT. In fact, the tumor volume following treatment was 
approximately 1/7 of the tumor volume in the control group two weeks after treatment 
(P < 0.01). No systemic toxicity, including obvious weight loss, or other apparent 
adverse effects were found throughout the study. These results showed that 
Ga-4cisPtTPyP is capable of tumor inhibition toward the Colon26 cell line and could 
be an effective agent in future clinical applications for PDT. 
1.4 Conclusions 
In summary, to obtain potential photosensitizing anticancer agents with improved 
hydrophilicity and high tumor accumulation, a porphyrin framework, Pt(II)-based 
chemotherapeutic drug, and the metal ion gallium(III) were combined and 
characterized. Compared with 4cisPtTPyP, the mixed-metal porphyrinate, 
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Ga-4cisPtPyP, is an efficient singlet oxygen generator because of heavy atom effect, 
more acidic pKa, and localization in cytosol. It also showed negative dark cytotoxicity 
caused by more hydrophilicity and slower and lower cellular uptake. We proposed 
that the excellent photocytotoxicity, interaction with DNA, and apoptosis pathway 
could contribute to the anticancer activity of Ga-4cisPtPyP. Biodistribution studies 
revealed a prominent accumulation in tumors (tumor/muscle ratio > 9). In an in vivo 
PDT assay, Ga-4cisPtTPyP almost completely inhibited tumor growth over two weeks, 
which demonstrated impressive photodynamic cancer-killing efficacy. Based on these 
experiment evidences, Ga-4cisPtTPyP could be a highly promising anticancer agent 
for use in PDT. 
 
Fig. 1-5. (a) Relative weight after treatment of Ga-4cisPtTPyP on BALB/c mice; (b) 
Tumor growth curves of control group and Ga-4cisPtTPyP treated group. The tumor 
volumes were normalized to their initial sizes. The error bars represent the standard 
deviations of 5 mice per group. *, p < 0.05; **, p < 0.01. 
 34 
Chapter 2   





Photodynamic therapy (PDT), combining three components: light, singlet oxygen 
(1O2), and a photosensitizer, is a curative treatment widely used for the treatment of 
various forms of cancer [73]. Irradiated with light of wavelengths in the range 600–
800 nm, the therapy determines singlet oxygen (1O2) generation, which is an actively 
cytotoxic agent in PDT. For successful PDT treatment, an efficient photosensitizer 
must meet several conditions: (1) no cytotoxicity under dark, (2) reasonable cytotoxic 
1O2 generation ability under light, (3) a high absorption coefficient in the long 
wavelength region, (4) reasonable water-solubility, and (5) selective accumulation to 
the tumor tissue [74]. 
The major drawback of porphyrins is the poor solubility in most of the organic 
solvents. It can be increased by substitution at the central or peripheral positions with 
several functional groups [75]. To increase the utility of porphyrins in PDT, chemical 
modification of the porphyrin ring has been extensively investigated. The 
photophysical and photochemical properties of porphyrin derivatives can be tuned by 
varying the central metal atom resulting in a hypsochromic shift in the absorption 
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spectra, particularly, closed-shell and diamagnetic ions [76-78]. The presence of the 
heavy metal in porphyrins can decrease the energy difference between the singlet 
state and the excited triplet state of photosensitizers and increase its triplet state 
lifetime, in a process known as the heavy-atom effect [79]. Metalloporphyrin 
complexes containing indium (III), zinc (II) and some other metals have been proved 
as highly promising photosensitizers for PDT due to their intense absorption in the 
near infrared region of the visible light [80, 81]. 
Previous studies have shown that Ga-4cisPtTPyP can be used as an efficient 
anticancer agent for PDT. In an extension of my work directed to investigate the 
effect of metalation of platinum-porphyrin complexes as efficient photosensitizers in 
the area of PDT, I have also addressed my attention to inserting heavy metals (indium 
(III) and zinc (II)) to the core of this series of complexes. We hypothesized that the 
insertion of heavy metals will alter the photophysical and photochemical properties 
which, in combination with increased 1O2 quantum yields, will enhance the PDT 
efficacy. 
2.2 Experimental  
2.2.1 Materials  
The percentages of cells in G1-G0, S, and G2-M phases were acquired on a BD 
FACSVerse™ flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). The other 
machines and reagents used are introduced in the Experimental of Chapter 1. 
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2.2.2 Synthesis  
MTPyP (M = Zn and In). ZnTPyP and InTPyP were synthesized by reacting H2TPyP 
with zinc chloride and indium chloride respectively, according to the slightly 
modified methods [82, 11]. Both of them were characterized by 1H NMR, ESI-MS, 
and elemental analysis. 
Synthesis of Zn-4cisPtTPyP. Cisplatin (0.129 mmol, 39 mg) and silver nitrate (0.129 
mmol, 22 mg) were dissolved in 2 mL of N,N-dimethylformamide (DMF) and stirred 
at room temperature for 24 h. The resulted turbid solution was filtered to remove 
white silver chloride. The light yellow colored filtrate was added to a solution of 
ZnTPyP (0.0325 mmol, 22 mg) in 2 mL of DMF. After stirring at 50°C for 72 h, the 
mixture was cooled down to ambient temperature and then precipitated with diethyl 
ether. The solid was filtered and further washed with cold methanol, chloroform and 
diethyl ether. The solid was dried in vacuum and complex Zn-4cisPtTPyP was 
obtained as a purple powder. 
Applying a method similar to that described for complex Zn-4cisPtTPyP, complexes 
Zn-4transPtTPyP, In-4cisPtTPyP, and In-4transPtTPyP were synthesized by reacting 
with the corresponding metalloporphyrins (MTPyP). Their spectroscopic and 
analytical data are provided in the Supporting Information. 
Zn-4cisPtTPyP. Yield: 73%. 1H NMR (400 MHz; DMSO-d6): δ 9.18 (o-pyridyl, d, 
8H, J = 6.4 Hz), 8.95 (β-pyrrole, s, 8H), 8.39 (m-pyridyl, d, 8H, J = 6.4 Hz), 4.98 
(NH3, s, 12H), 4.50 (NH3, s, 12H); Elemental analysis calcd (%) for 
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C40H48Cl4N20O12Pt4Zn·DMF·5H2O: C 24.00, H 3.02, N 13.67; found: C 23.72, H 
2.69, N 13.31. 
Zn-4transPtTPyP. Yield: 62%. 1H NMR (400 MHz; DMSO-d6): δ 9.18 (o-pyridyl, s, 
8H), 8.95 (β-pyrrole, s, 8H), 8.38 (m-pyridyl, s, 8H), 4.50 (NH3, m, 24H); Elemental 
analysis calcd (%) for C40H48Cl4N20O12Pt4Zn·3DMF·2CH3OH·H2O: C 26.74, H 3.45, 
N 14.07; found: C 26.41, H 3.14, N 13.87. 
In-4cisPtTPyP. Yield: 71%. 1H NMR (400 MHz; DMSO-d6): δ 9.25 (o-pyridyl, d, 
8H, J = 6.0 Hz), 9.16 (β-pyrrole, s, 8H), 8.45 (m-pyridyl, s, 8H), 4.99 (NH3, s, 12H), 
4.52 (NH3, s, 12H); Elemental analysis calcd (%) for C42H51Cl4N20O14Pt4In·3H2O: C 
22.50, H 2.99, N 12.50; found: C 22.54, H 3.08, N 12.51. 
In-4transPtTPyP. Yield: 66%. 1H NMR (400 MHz; DMSO-d6): δ 9.24 (o-pyridyl, s, 
8H), 9.16 (β-pyrrole, s, 8H), 8.44 (m-pyridyl, s, 8H), 4.54 (NH3, m, 24H); Elemental 
analysis calcd (%) for C42H51Cl4N20O14Pt4In·CH3OH·3H2O: C 23.65, H 2.61, N 12.83; 
found: C 23.76, H 3.01, N 12.80. 
2.2.3 Singlet oxygen quantum yields 
Singlet oxygen quantum yields (Φ∆) were determined by photooxidation of 
9,10-dimethylanthracene (DMA) using steady state photolysis and 
tetraphenylporphyrin (TPP) in dimethylsulfoxide (DMSO) as reference ( Φ∆R  =
 0.52) [50-52, 22]. DMA solutions (1.45 × 10-4 M in DMSO, 1.5 mL) were mixed 
with the photosensitizer in a 1 cm quartz cuvette. The initial absorbance reading of the 
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reaction mixture at 401nm was taken, and then the cuvette was irradiated by a 50W 
LED light. The kinetics of DMA photooxidation were carried out by following the 
decrease of the absorbance (A) at λmax = 401nm. The observed rate constants were 
obtained by a linear least-squares fit of the semilogarithmic plot of Ln A0/A versus 
time. The singlet oxygen generation by a photosensitizer was calculated using the 
following equation: 




Where KR and KS are the slopes of the kinetics of DMA disappearance 
photosensitized by the sample and standard, respectively. IR and IS are the total light 
intensities absorbed by sample and standard, respectively. All measurements were 
performed in three times. 
2.2.4 Cell cycle perturbations 
The effect of In-4cisPtTPyP and cisplatin on the cell cycle was assessed by flow 
cytometry by measuring the percentages of cells in G1-G0, S, and G2-M phases, with 
and without irradiation after treatment with the conjugate. The treated cells were fixed 
in 70% ice-cold ethanol and the samples were concentrated to remove of ethanol. The 
cells were treated with RNase A and PI staining solution was added to the samples to 
stain cellular DNA for 20 min at 37°C in dark. The cell cycle distribution was 
analyzed by flow cytometry [83]. 
2.2.5 Animal model  
 39 
Animal experiments were conducted in strict accordance with the Guidelines for the 
Care and Use of Laboratory Animals of Kanazawa University. The animal 
experimental protocols used were approved by the Committee on Animal 
Experimentation of Kanazawa University (Permit Number: AP-153334). Female 
BALB/c mice (5 weeks) were purchased and the Colon26 tumor models were 
generated by subcutaneous injection of 1×106 cells into the right and left shoulders 
respectively. The mice were used for photodynamic therapy and biodistribution when 
the tumor volume reached about 100 mm3. 
2.2.6 In vivo biodistribution 
To investigate the in vivo uptakes of In-4cisPtTPyP, biodistribution studies with 
complex’s specialty to particular organs were conducted. In-4cisPtTPyP was 
administered to the mice at doses of 8.25 μmol/kg body weight. The main tissues and 
blood were collected at 2 h, 6 h, 24 h, and 48h after administration. 
Tetramethylammonium hydroxide (TMAH) as an aqueous 25% solution was added to 
each sample and incubated for 24 h at 60°C. After centrifugation, 0.5 mL of 
supernatant was mixed with 4 mL of the solution containing HNO3 1% and Triton 
X-100 0.01%. Treated samples were analyzed by monitoring Pt content and In 
content by ICP-AES. 
2.2.7 Photodynamic therapy 
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When the tumor size reached ~100 mm3, eight mice were randomized into 2 groups. 
Mice in group 1 were injected into the tail vein with In-4cisPtTPyP at a drug dose of 5 
μmol/kg of body weight. Mice in group 2 were not administrated as control. The 
tumor of left shoulder on each mouse in these two groups was irradiated for 30 min 
which was divided into three ten-minute periods with a five-minute break between 
each period, and the right tumor was kept in dark. Mice were monitored for tumor 
growth and body weight up to 12 days post PDT treatment. Tumor size was measured 
with a digital caliper and tumor volume was calculated as volume = LW2/2, where L 
is the longer diameter and W is the shorter diameter. 
2.2.8 Statistical analysis 
Data are expressed as means ± standard deviations where appropriate. Analyses of in 
vitro PDT assay were performed using GraphPad Prism Software, version 5 for 
Windows (GraphPad Software, San Diego, CA, USA). In vivo PDT experiment, 
differences were identified using one-way analysis of variance (ANOVA) and were 
considered statistically significant when p < 0.05. 
2.3 Results and Discussion 
2.3.1 Synthesis and characterization 
Cisplatin, transplatin, H2TPyP, and MTPyP were synthesized according to the 
references reported. Zn-4cisPtTPyP, Zn-4transPtTPyP, In-4cisPtTPyP, and 
In-4transPtTPyP were synthesized following the methodologies illustrated in Scheme 
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2-1. In brief, MTPyP, obtained by treating H2TPyP with the corresponding metal 
halide, was reacted with cisplatin or transplatin to provide these four cationic 
metalloporphyrins in good yields. These complexes were characterized by 1H NMR, 
elemental analysis, and UV/Vis spectroscopy and fluorescence spectroscopy.  
Generally, porphyrins have unique optical characteristics with a strong absorption of 
Soret band around 420 nm representing S0 → S2 transition, and several weak Q bands 
around 550-650 nm arising from S0 → S1 transition. The Q bands consist of multiple 
peaks caused by different vibrational modes. After inserting different transition metals 
into the core of porphyrins, the Q bands undergo major changes, which makes a 
significant contribution on PDT. As shown in Table 2-1, all of these 
metalloporphyrins experienced a bathochromic shift of 4-11 nm, resulting in λmax 
values of 603 nm for Zn-4cisPtTPyP and Zn-4transPtTPyP, and 605 nm for 
In-4cisPtTPyP and In-4transPtTPyP in DMSO. The reason can be due to the 
destabilization of the π-system resulting in a smaller HOMO-LUMO band gap. Upon 
excitation at λmax (434 nm for Zn-4cisPtTPyPand Zn-4transPtTPyP, 433 nm for 
In-4cisPtTPyPand In-4transPtTPyP), these complexes showed two emission peaks 
around 610 nm and 655 nm in DMSO (Fig. 2-1). 
Solubility plays an important role in the field of PDT, which markedly affects the 
absorption, biodistribution and efficacy. With the goal of water-soluble complexes, 
the lipophilic and hydrophilic properties were analyzed by the partition coefficient in 
n-octanol/water system. As presented in Table 2-2, In- and Ga-based complexes 
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Scheme 2-1. Synthesis of Zn-4cisPtTPyP, Zn-4transPtTPyP, In-4cisPtTPyP, and 
In-4transPtTPyP.  
 
displayed comparatively more water-soluble than 4cisPtTPyP and Zn-based 
complexes, and platinum-coordinated metalloporphyrins (Zn/In/Ga-4PtTPyP, 
4cisPtTPyP) also showed more hydrophilic than MTPyP (M = Zn, In, and Ga). We 
speculated on the reason of the overall charge difference. When the metal ion is 
inserted into the core of the porphyrin framework with acetic acid as the reaction 
solvent, the two hydrogens present as −NH protons at the center core are substituted 
for acetate ions. For example, In has an oxidation state of +3 and, after replacing two 
central hydrogens, the charge of InTPyP moiety is +1. Afterwards, the overall charges 
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reached +5 by coordinating with four platinum groups. The ranking of overall charges 
for these complexes, is listed as follows: 
In-4cisPtTPyP, In-4transPtTPyP, Ga-4cisPtTPyP, and Ga-4transPtTPyP (5+) > 
Zn-4cisPtTPyP and Zn-4transPtTPyP (4+) > InTPyP and GaTPyP (1+) > ZnTPyP (0) 
But for logP values (Table 1-2 and Table 2-2), with increasing the overall charge, the 
logP value was decreased, and meanwhile, water solubility was improved. Therefore, 
the hydrophilicities of these complexes were increased by conjugation of the platinum 
moieties and insertion of metal ions to the porphyrin frame.  
2.3.2 Aggregation studies 
The aggregation behaviors of these complexes were investigated at different 
concentrations in DMSO, regarding the fact that the aggregation state of 
photosensitizers is an important factor concerned with their photodynamic activities 
(Fig. 2-2). When increasing the concentration of these complexes, the intensity of the 
bands was also increased and no any new bands appeared. The Lambert–Beer law 
was obeyed at the concentrations employed from 0.5 μM to 10 μM. All of them did 
not show aggregation at these concentrations in DMSO. For Zn (II)-based porphyrins, 
the oxidation state of porphyrinate core is 0. Whereas, In (III) and Ga (III) complexes 
are +1 for the porphyrin cores, which can prevent stacking and aggregation of the 
complexes In-4PtTPyP and Ga-4PtTPyP. This is significant since aggregation can 
greatly decrease the effectiveness of the photosensitizer in PDT. 
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Table 2-1 Spectral data of complexes (5 μM) in DMSO at room temperature. 
  complex λmax / nm (ε / 104 M-1·cm-1) λem / nm 
Zn-4cisPtTPyP 434 (38.8), 562 (2.0), 603 (0.6) 611,656 
Zn-4transPtTPyP 434 (34.5), 562 (2.0), 603 (0.6) 611,656 
In-4cisPtTPyP 433 (33.9), 564 (1.8), 605 (0.7) 612,659 
In-4transPtTPyP  433 (6.5), 564 (0.4), 605 (0.2) 612,659 
  
 
     
Fig. 2-1. Emission spectra of M-4PtTPyP recorded upon excitation at λmax in DMSO.
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2.3.3 Photodegradation studies  
Photosensitizers can undergo two types of photochemical reactions, photobleaching 
and phototransformation. The progress of photobleaching can be studied in the UV–
vis through the disappearance of absorption bands. Opposite to this, in the 
phototransformation process, an appearance of new absorption bands in the visible 
region can be observed resulting in the loss of the dye colour [84]. An ideal 
photosensitizer should have the ability to remain in an average time to show 
photodynamic activity in vivo. For this reason, it is especially important to determine 
the photostability behavior of a photosensitizer. Generally, porphyrins exhibit an 
optimal stability against decomposition caused by irradiation. In this study, 
photodegradation properties of Zn-4PtTPyP, In-4PtTPyP, and Ga-4PtTPyP were 
investigated in DMSO solutions by monitoring the collapse of their absorption bands 
under light irradiation (Fig. 2-3, Fig. 2-4, and Fig. 2-5). The band shapes of the 
spectra of Zn-4PtTPyP and Ga-4PtTPyP did not deteriorate under light irradiation and 
their intensities were showed to be decreasing in Soret and Q bands instead of 
deformation of the shape of bands or formation of new bands, indicating that the 
photodegradation occurred without the phototransformation. The spectral changes 
observed for In-4PtTPyP during irradiation confirmed that the photobleaching 
co-occurred with the phototransformation showing a new peak in Q bands, which 
means In-4PtTPyP showed lower stability during the photodegradation studies. It 
could be attributed to larger indium(III) atom located up to the porphyrin plane moves 
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away easily from this plane. Accordingly, the stability of these complexes were in the 
order of metal ion radii, that is, Zn-4PtTPyP > Ga-4PtTPyP > In-4PtTPyP (Fig. 2-6). 
 
 
Table 2-2 The logP (n-octanol/water) values and quantum yields of singlet oxygen. 
 
Compound   logP    Φ∆ 
Zn-4cisPtTPyP -1.63±0.16 0.86±0.05 
Zn-4transPtTPyP -1.59±0.11 0.80±0.27 
In-4cisPtTPyP -1.97±0.19 0.76±0.07 
In-4transPtTPyP -1.92±0.26 0.62±0.28 
Ga-4cisPtTPyP -2.06±0.21 0.76±0.08 
Ga-4transPtTPyP -1.91±0.20 0.63±0.09 
4cisPtTPyP -1.77±0.08 0.57±0.03 
ZnTPyP 1.19±0.07 0.35±0.07 
InTPyP 0.96±0.06 0.35±0.10 




Fig. 2-2. The aggregation behaviors of Zn-4PtTPyP and In-4PtTPyP were 
investigated at different concentrations ranging from 0.5 μM to 10 μM in DMSO: (a) 






Fig. 2-3. Changes in the absorption spectra of Zn-4cisPtTPyP (10 μM, above) and 





Fig. 2-4. Changes in the absorption spectra of In-4cisPtTPyP (10 μM, above) and 




Fig. 2-5. Changes in the absorption spectra of Ga-4cisPtTPyP (10 μM, above) and 




Fig. 2-6. Relative changes in the absorbance of Zn-4PtTPyP, In-4PtTPyP, and 




2.3.4 Singlet oxygen quantum yields 
Since singlet oxygen is recognized as the major cytotoxic factor in PDT therapy, an 
efficient photosensitizer must be effectively generating singlet oxygen. To evaluate 
the photosensitizing efficiency of the complexes, the singlet oxygen production was 
detected by using the photooxidation reaction of DMA, and the kinetics of DMA 
photooxidation was assessed by observation of the absorbance decreasing at 401 nm 
(Table 2-2). The 1O2 quantum yield corresponds to the following order: 
Zn-4cisPtTPyP and Zn-4transPtTPyP > In-4cisPtTPyP, In-4transPtTPyP, 
Ga-4cisPtTPyP, and Ga-4transPtTPyP > 4cisPtTPyP > MTPyP   
Obviously, the Φ∆ of these cationic metalloporphyrinates M-4PtTPyP were greater 
than that of metal-free porphyrin 4cisPtTPyP, which could be due to the heavy atom 
effect. For these three different kinds of metal inserted complexes, cis-isomers 
generated more singlet oxygen than trans-isomers. Compared Pt-based porphyrinates 
with MTPyP, a significant improvement was found in 1O2 quantum yield by 
introducing platinum groups into the peripheral pyridine groups. For our complexes, 
they were Pt(II) state and their 1O2 production mechanism might be related with 
metal-to-ligand charge transfer mechanism. Since the release of the Pt moieties from 
the porphyrinate frame (vide infra) might not be excluded from the possible 
mechanism of the 1O2 production, we are going to study the detailed mechanism in 
further. Correspondingly, these complexes showed high singlet oxygen quantum 
yields, which implied that they are highly efficient singlet oxygen generators. 
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2.3.5 In vitro PDT  
Ideal photosensitizers are desirable to be minimally toxic under dark, as they should 
only cause cancer cell death in the presence of light treatment. We first examined the 
cytotoxicity of these metalloporphyrins in the absence of activating light before 
evaluating the photocytotoxic efficacy. Cell viability was assessed by a MTT assay on 
mouse Colon26 cells. Surprisingly, In and Ga complexes (In-4cisPtTPyP, 
In-4transPtTPyP, Ga-4cisPtTPyP, and Ga-4transPtTPyP) showed low dark toxicity, 
while Zn and metal-free complexes (Zn-4cisPtTPyP, Zn-4transPtTPyP, and 
4cisPtTPyP) had comparable anticancer activity to cisplatin under dark. As indicated 
(Introduction), an efficient photosensitizer should not exhibit cytotoxicity under dark. 
In view of this point, Zn-4PtTPyP are not good candidates for PDT. 
To investigate the photosensitizing potential of these complexes, the 
photocytotoxicity of the complexes toward Colon26 and Sarcoma180 cell lines were 
evaluated using the MTT assay. Table 2-3 shows the IC50 values acquired after 24 h 
incubation, irradiated for 30 min, and incubated for 48 h. All of these complexes 
displayed marvelous cytotoxic activities upon illuminating with LED light. 
Cis-isomers were more efficient than trans-isomers, which was in accord with the 
results of singlet oxygen quantum yields. On the other hand, no significant difference 
between metalloporphyrin complexes and metal-free porphyrin complex was found, 
suggesting that there is no much effect on anticancer activity by central metal ions 
though the SOQ of them are different. As can be seen, a 14-fold (Sarcoma180 cell 
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Table 2-3 IC50 values (μM) toward Colon26 and Sarcoma180 cell linesa. 
 
Compound 
Colon26  PIb  Sarcoma180  PIb                    
 
In dark With light  Dark/Light  In dark With light  Dark/Light 
Zn-4cisPtTPyP 3.76±1.18 0.11±0.04  34  3.81±2.11 0.10±0.04  38 
Zn-4transPtTPyP 11.30±5.18 0.06±0.04  188  4.57±1.73 0.04±0.03  114 
In-4cisPtTPyP 32.89±4.54 0.08±0.06  411  43.19±3.74 0.07±0.01  617 
In-4transPtTPyP 41.68±20.58 0.11±0.06  379  44.39±18.54 0.14±0.03  317 
4cisPtTPyP 10.55±1.39 0.14±0.01  75  3.09±1.29 0.17±0.08  18 
ZnTPyP+4cisplatin 13.04±0.57 5.49±0.36  2  18.01±2.12 7.80±2.18  2 
cisplatin 3.62±1.00 3.25±0.91  1  9.34±3.23 16.02±6.62  1 
      a All compounds were examined in a set of experiments repeated three times independently toward Colon26 and Sarcoma180 cell lines. 
      b PI: phototoxic index. 
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line) to 15-fold (Colon26 cell line) increase in phototoxicity after coordinated with 
cisplatin or transplatin indicated that peripheral combination of platinum groups make 
a considerable contribution to the anticancer activity. As a better control, the 
photocytotoxicity of a mixture of MTPyP (M = Zn and Ga) and 4 equivalent cisplatin 
was also compared with M-4PtTPyP. The anticancer effect of these mixture were 
significantly lower than those of M-4PtTPyP against both cancer cell lines, 
completely proving the success of our strategy of combination therapy. In addition, 
the consistency of the order of photocytotoxicity and singlet oxygen quantum yields 
clarified that 1O2 is a key intermediate in photodynamic action. 
2.3.6 Cell cycle perturbations 
To better verify the role of In-4cisPtTPyP in inducing cancer cell growth alterations, the 
effect on cell cycle progression was investigated on Colon 26 cell line upon 24 h of 
incubation in dark followed by 30 min of light exposure. The cells were treated with 
different concentrations of cisplatin and In-4cisPtTPyP and analyzed by flow 
cytometry after staining with propidium iodide (Fig. 2-7 and Fig. 2-8). Cisplatin 
arrested cell cycle in the G2/M phase. By comparison with In-4cisPtTPyP-treated 
cells without irradiation, no significant change in cell cycle population was produced, 
which suggested that the conjugate does not induce cell cycle arrest at any phase of 
the cell cycle. Even if further investigation will be need, it is possible to hypothesize 





Fig. 2-7. Cell cycle analysis of cisplatin by flow cytometry. Colon26 cells were 





Fig. 2-8. Cell cycle analysis of Colon 26 cells by flow cytometry. Cells were treated 
with In-4cisPtTPyP for 48 h. 
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2.3.7 In vivo biodistribution  
The biodistribution study of In-4cisPtTPyP was evaluated using Colon26 
tumor-bearing mice, and analysis of this complex in each organ was performed using 
ICP-AES. As given in Fig. 2-9, in the early stages after the injection, In-4cisPtTPyP 
accumulated in the lung, liver, and kidney. As time was extended, high concentration 
of In-4cisPtTPyP was observed in liver by 6 h post-injection. In-4cisPtTPyP showed 
high accumulation in the spleen within 24 h post-injection, which may be the reason 
that the spleen is the largest immune organ. After 24 h post-injection, the 
concentrations of In-4cisPtTPyP reduced in all organs, and it was cleared from the 
blood, stomach, intense, heart, muscle, and brain with 48 h post-injection. Considered 
of the changes of In-4cisPtTPyP in the organs, it could generally be excreted from the 
mice as time prolonged. 
The integrity of In-4cisPtTPyP was evaluated by analyzing the Pt/In ratios in tissues 
at different time points (Table 2-4). The ratio of Pt concentration and In concentration 
theoretically should be 4, whereas the ratios in liver, kidney, and tumor listed in Table 
2-4 as examples were far removed from it within 2 h post-injection, which indicated 
that In-4cisPtTPyP was metabolically degraded quickly and the platinum groups were 
detached from the gallium framework in vivo.  
2.3.8 In vivo PDT on subcutaneous tumor-bearing mice 





Fig. 2-9. Pt concentration (above) and In concentration (below) in each tissue of mice 
at 2, 6, 24, and 48 h after intravenous injection of In-4cisPtTPyP (Bld = blood; Spl = 
spleen; Pan = pancreas; Sto = stomach; L-Int = large intestine; S-Int = small intestine; 
Kid = kidney; Liv = liver; Hrt = heart; Lng = lung; Mus = muscle; Brn = brain; Tum = 
tumor).
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Table 2-4 Pt and In concentrations (μmol/kg) of In-4cisPtTPyP and distribution ratios in the liver, kidney, and tumor at different time points. 
  2h             6h    24h    48h 
  CPt CIn CPt/CIn   CPt CIn CPt/CIn    CPt   CIn CPt/CIn    CPt   CIn CPt/CIn 
Liver 136.53  92.10  1.48  
 
148.81  111.13  1.34  
 
108.57  104.35  1.04  
 
36.66  34.99  1.05  
Kidney 94.63  64.28  1.47  
 
105.31 90.71 1.16  
 
88.56  76.59  1.16  
 
8.92  18.89  0.47  
Tumor 17.04  27.13  0.63    21.37 42.71 0.50    13.47  42.23  0.32    0.22  19.25  0.01  
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properties, variable tissue oxygenation, as well as unexpected photophysical and 
photochemical changes of photosensitizers [85]. Throughout the study, no other 
apparent adverse effects were found at the dose of 5 μmol/kg of body weight. 
Therefore, In-4cisPtTPyP cannot induce severe side-effects at this dose in PDT. 
Previous study has demonstrated that Ga-4cisPtTPyP can inhibit the tumor growth in 
Colon26 tumor-bearing mice with tumor accumulation. To assess the phototoxic 
activity of In-4cisPtTPyP, tumor growth and body weight were examined after 
administration. As indicated in Fig. 2-10, In-4cisPtTPyP efficiently inhibited the 
tumor growth of treated groups with light and remained for two weeks after PDT. In 
fact, the mean tumor volume treated with In-4cisPtTPyP was about 1/4 - 1/5 of the 
mean volumes in these three control groups at 14 days of administration (P < 0.01). 
During the initial stage of the treatment, body weight loss was observed in 
In-4cisPtTPyP-treated group on day 2, but no significant change in the body weight 
was noticed in these two groups. According to these results, it can be concluded that 
In-4cisPtTPyP is highly effective for tumor inhibition on Colon26 cell line and may 
be an promising agent in future clinical application for PDT. 
2.4 Conclusions 
In the present work, Zn-4cisPtTPyP, Zn-4transPtTPyP, In-4cisPtTPyP, and 
In-4transPtTPyP were synthesized for the first time. We demonstrated the impact of 
the presence of heavy metals, Zn, In, and Ga, on the photophysical and photochemical 
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properties as well as PDT efficacy. These properties were affected significantly by 
changing the central metal cation in the studied platinum-porphyrin complexes. 
Additionally, the increasing of atom size of central metal enhanced the efficiency of 
singlet oxygen generation. Though Zn-Pt porphyrins can generate the largest singlet 
oxygen and show stable under irridiation, we do not recongnize that these two 
complexes have the potential to be a better candidate for PDT since their poor 
solubility and low PIs in vitro PDT assay. However, In-Pt porphyrins showed good 
photophysical and photochemical properties and it can be good candidates as Type II 
photosensitizers in photodynamic therapy applications. 
 
 
Fig. 2-10. (a) Relative weight after treatment of In-4cisPtTPyP on BALB/c mice; (b) 
Tumor growth curves of control group and In-4cisPtTPyP treated group. The tumor 
volumes were normalized to their initial sizes. The error bars represent the standard 
deviations of 4 mice per group. *, p < 0.05; **, p < 0.01. 
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Chapter 3    





Platinum complexes, such as cisplatin, carboplatin, and oxaliplatin 
[Pt(dach)(C2O4)], have been used as a first-line therapy to treat colorectal 
cancer [86, 87].  As a third generation platinum anticancer drug, oxaliplatin is 
still constrained by dose-limiting side-effects and acquired resistance [88], 
though it proves to be relatively easy to handle and well tolerated [89]. The 
most frequent toxic effect for oxaliplatin is peripheral sensory neuropathy 
toxicity, usually resulting in dose modification [90]. Accumulating anticancer 
drugs in solid tumor tissue is an attractive strategy for improving the treatment 
efficacy of platinum-based chemotherapy [91].  
Porphyrins are thermodynamically and kinetically stable, and show great 
retention or accumulation in tumors by preferentially binding to low density 
lipoproteins [16, 92]. Porphyrin-based photosensitizers are effective templates 
for photodynamic therapy (PDT). They combine a photosensitizer, light source, 
and tissue oxygen that can lead to the chemical destruction of some superficial 
and localized cancers, as well as wet age-related macular degeneration [93-94, 
73]. Under illumination, photosensitizers are activated and induce energy 
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transfer to produce highly toxic reactive oxygen species, mainly singlet oxygen 
(1O2), which can kill cells by apoptosis or necrosis [95]. Therefore, porphyrins 
as a good carrier could deliver platinum drugs to tumor tissue and can also be 
used in PDT. 
Despite the advantages of porphyrin-based treatments, the notorious 
insolubility and aggregation of porphyrins in aqueous solutions negatively 
affects their cellular uptake and restricts in vivo activity and applications [96, 
97]. Consequently, a new tetracationic porphyrin, 4Pt(dach)ClTPyP, was 
synthesized by coordinating a pyridyl porphyrin to Pt(dach)Cl2, to improve 
hydrophilicity and eliminate the formation of aggregates by increasing the 
electrostatic repulsion from charged functional groups [98, 99]. This complex 
showed excellent photocytotoxicity in vitro and in vivo. With accumulation in 
tumor tissue, 4Pt(dach)ClTPyP completely killed tumor cells, not simply 
displaying inhibition of tumor growth. The reasons for cell death may be 
attributed to high singlet oxygen quantum, internalization into nucleus [35], and 
an apoptosis pathway. As far as we know, tetraplatinated metal-free porphyrins 
have not yet been investigated for in vivo PDT. 
3.2 Experimental  
3.2.1 Materials  
Fluorescence of caspase activity assay was measured with a fluorescence microplate 
reader (MTP-800; Corona Electric Co., Ibaragi, Japan). Ac-DEVD-MCA 
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(Ac-Asp-Glu-Val-Asp-MCA) for caspase activity assay was purchased from Peptide 
Institute (Osaka, Japan). The other machines and reagents used are introduced in the 
Experimental of Chapter 1. 
3.2.2 Synthesis of 4Pt(dach)ClTPyP 
5,10,15,20-Tetra(4-pyridyl)-21H,23H-porphine (H2TPyP) and Pt(dach)Cl2 were 
synthesized according to the slightly modified methods as showed in Scheme 3-1. 
Pt(dach)Cl2 (0.129 mmol, 49 mg) and silver nitrate (0.129 mmol, 22 mg) were 
dissolved in 2.5 mL of N,N-dimethylformamide (DMF) and stirred at 60°C for 24 h. 
The resulted turbid solution was filtered to remove white silver chloride. The light 
yellow colored filtrate was added to a solution of H2TPyP (0.0325 mmol, 20 mg) in 2 
mL of DMF. After stirring at 50°C for 72 h, the mixture was cooled down to ambient 
temperature and then precipitated with diethyl ether. The solid was filtered and further 
washed with cold water, cold acetone, chloroform, and diethyl ether. The solid was 
dried in vacuum and 4Pt(dach)ClTPyP was obtained as a purple powder (57 mg, 
78%). 1H NMR (400 MHz; DMSO-d6): δ 9.23 (o-pyridyl, d, 8H), 9.02 (β-pyrrole, s, 
8H), 8.51 (m-pyridyl, d, 8H, J = 6.4 Hz), 6.67-5.74 (NH2, m, 16H), 2.04 (CH, m, 8H), 
1.59-1.16 (CH2, m, 32H), 7.95 (CH, DMF), 2.89 (CH3, DMF), 2.73 (CH3, DMF), 2.09 
(CH3, CH3COCH3); Elemental analysis calcd (%) for 
C64H82Cl4N20O12Pt4· 4DMF· CH3COCH3: C 36.52, H 4.24, N 12.73; found: C 36.54, 
H 4.47, N 12.95.  
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3.2.3 Determination of caspase activity 
After treatment with 4Pt(dach)ClTPyP for 6 hours, cells were washed PBS, irradiated 
for 30 min or kept in dark, and incubated for different times. Cells were collected and 
lysed in lysis buffer (1% Triton X-100, 0.32 M sucrose, 5 mM EDTA, 10 mM 
Tris-HCl, pH 8, 2 mM dithiothione, 2 mM phenylmethanesulfonyl fluoride) for 20 
min at 4°C followed by centrifugation (10,000g) for 30 min. The cytosolic extracts 
were mixed with 5 μM Ac-DEVD-MCA (Ac-Asp-Glu-Val-Asp-MCA) in reaction 
buffer (100 mM HEPES, 10% sucrose, 5 mM dithiothreitol). Fluorescence was 
measured after 3 h (excitation wavelength, 365 nm; emission wavelength, 460 nm) 
with a fluorescence microplate reader.  
3.3 Results and Discussion 
3.3.1 Synthesis and characterization 
We used H2TPyP as the photosensitizing unit and the Pt(dach) group as the 
cytostatic moiety. Scheme 3-1 illustrates the synthetic route for formation of 
4Pt(dach)ClTPyP, which was characterized by 1H NMR (Fig. 3-1), elemental 
analysis, UV/Vis spectroscopy, and fluorescence spectroscopy (Fig. 3-2). Upon 
excitation at 425 nm, 4Pt(dach)ClTPyP showed a strong emission peak at 647 
nm in DMSO. The UV/Vis spectra of 4Pt(dach)ClTPyP exhibited a strong 
Soret band centered at 423 nm resulting from the increased average electron 
density of the porphyrin framework lowering the energy for electron transition, 
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and four Q bands at 516 nm, 550 nm, 589 nm, and 644 nm in DMSO. Strictly 
obeying the Beer–Lambert law, this complex did not aggregate at 
concentrations from 0.5 μM to 10 μM in DMSO and H2O (Fig. 3-3). It is 
meaningful for 4Pt(dach)ClTPyP since aggregation can greatly decrease the 
effectiveness of the photosensitizer in PDT. The hydrophilicity was also 
characterized by the partition coefficient in an n-octanol/water system. With a 
logP value of −1.56±0.24, 4Pt(dach)ClTPyP displayed moderate hydrophilicity, 

















Fig. 3-2. Emission spectrum recorded upon excitation at 425 nm of 4Pt(dach)ClTPyP 
(5 μM) in DMSO. 
 
 
Fig. 3-3. The aggregation behaviors of 4Pt(dach)ClTPyP were investigated at 
different concentrations ranging from 0.5 μM to 10 μM: (a) 4Pt(dach)ClTPyP 
in DMSO; (b) 4Pt(dach)ClTPyP in H2O. 
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3.3.2 Singlet oxygen quantum yields 
The mechanism of PDT involves transfer of energy from photochemical 
reactions. Singlet oxygen is considered a major cytotoxic factor responsible for 
the photodynamic effect [100]. Some literature data have reported a dramatic 
decrease of 1O2 in aqueous solutions because of the low lifespan of 1O2, which 
are 1–2 orders of magnitude shorter than in other organic solvents [101, 102]. 
Hence, singlet oxygen production from 4Pt(dach)ClTPyP was evaluated by 
9,10-dimethylanthracene in DMSO. The results showed a high singlet oxygen 
quantum yield (Φ∆ = 0.64 ± 0.09), implying that 4Pt(dach)ClTPyP is a highly 
efficient singlet oxygen generator and has considerable potential as a 
photosensitizer for PDT. 
3.3.3 Photobiological assays 
The dark cytotoxicity and photocytotoxicity of the complex toward Colon26 
and Sarcoma180 cell lines were tested using the MTT assay. As shown in Table 
3-1, 4Pt(dach)ClTPyP showed low dark toxicity with IC50 values of 12.50 and 
17.85 μM in Colon26 and Sarcoma180 cell lines. Once illuminated, it exhibited 
decreased cell viability and IC50 values were determined as 0.17 and 0.25 μM, 
respectively. After H2TPyP was coordinated to Pt(dach)Cl2, a large increase in 
photocytotoxicity toward both cell lines was found for 4Pt(dach)ClTPyP. 
Accordingly, peripheral combination of platinum groups to the porphyrin 
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framework, generating considerable Φ∆, makes a substantial contribution to 
photocytotoxicity, requiring further study to elucidate the mechanism. 
Meanwhile, the photocytotoxicity of a mixture of H2TPyP and 4 equivalents of 
Pt(dach)Cl2 was also studied as a control experiment. The IC50 values of this 
mixture (2.24 and 4.04 μM in Colon26 and Sarcoma180 cell lines) were 
significantly larger than those of 4Pt(dach)ClTPyP, completely proving the 
success of the combined effect between the porphyrin framework and the 
Pt(II)-based chemotherapy drug. 
 
    Table 3-1 IC50 values (μM) toward Colon26 and Sarcoma180 cell lines. 
Compound 
Colon26  Sarcoma180 
In dark With light  In dark With light 
[Pt(dach)Cl]4TPyP 12.50±5.98 0.17±0.09  17.85±0.80  0.25±0.09 
H2TPyP+4Pt(dach)Cl2  1.87±0.71 2.24±0.08   4.11±1.69  4.04±1.21 
Pt(dach)Cl2  1.37±0.53 3.40±1.93  12.84±1.30 13.08±1.41 
   All compounds were examined in a set of experiments repeated three times   
independently toward Colon26 and Sarcoma180 cell lines. 
 
3.3.4 Subcellular localization 
In order to investigate cell localization of the promising 4Pt(dach)ClTPyP 
complex, cellular uptake studies were performed. Colon26 cells were incubated 
 72 
with 4Pt(dach)ClTPyP for 2, 6, and 24 h, and the platinum content was 
determined in the cytosol, nucleus, and membrane fractions using ICP-AES. 
The data, reported as ng of platinum per million cells, are shown in Fig. 3-4a. 
From the results, 4Pt(dach)ClTPyP exhibited fast cellular uptake and reached a 
maximum concentration at 6 h. A large portion was detected in the cell 
membrane fraction containing mitochondria where heme is synthesized [103]. 
The complex was also distributed in the nucleus, which may result from 
platinum groups localizing in cell nuclei and insertion into DNA [35, 104]. On 
the other hand, 4Pt(dach)ClTPyP also showed an unignorable distribution in 
cytosol, which may cause mitochondrial damage that affects the energy 
production of cells, activating the caspase-3- and 9-mediated apoptotic pathway 
[105, 106].  
3.3.5 Apoptosis 
Porphyrin-based photosensitizers for PDT may be capable of inducing rapid 
release of cytochrome c and initiating an apoptotic cascade. After releasing 
mitochondrial cytochrome c into the cytosol, caspase-3 can be activated 
triggering apoptotic cell death [106, 107]. To identify whether caspase-3 is 
involved in PDT induced apoptosis, Ac-DEVD-MCA, a caspase-3-like 
proteinase substrate, was employed for estimating the catalytic activity of 
caspase-3. 4Pt(dach)ClTPyP-treated cells could not be triggered to active 




Fig. 3-4. (a) Cellular uptake following 4Pt(dach)ClTPyP treatment (15 μM for 
2 h, 6 h, and 24 h) in Colon26 cell line; (b) Effects of 
4Pt(dach)ClTPyP-induced caspase-3 activation in Colon26 cells. Colon26 cells 
were incubated with 0.1 μM 4Pt(dach)ClTPyP for 24 h with light irradiation, 
and Ac-DEVD-MCA was used as the substrate for caspase-3. The caspase-3 
activity of control cells was set to 100% and the relative changes in the activity 
under light are shown. 
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light irradiation (Fig. 3-4b), indicating that 4Pt(dach)ClTPyP can lead to 
induction of cell apoptosis involving caspase-3 with light. 
3.3.6 In vivo biodistribution  
The in vivo pharmacokinetic activity of 4Pt(dach)ClTPyP after tail-vein 
administration was investigated in Colon26 tumor-bearing mice and the results 
are given in Fig. 3-5. After intravenous administration, the complex 
accumulated in the spleen, kidney, liver, and lung during the early stage. After 
24 h post-injection, the Pt concentration dramatically reduced in blood. Using 
blood and muscle as two reference tissues, the concentration ratios of 
tumor-to-blood and tumor-to-muscle increased with time, reaching 2.9 and 31.5 
at 48 h respectively. The preferential uptake of it in tumors was most likely 
induced by binding to low density lipoproteins (LDL), since cancer cells 
overexpress LDL which would play an important role in transportation of 
porphyrins to tumor cells [72, 108]. 
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Fig. 3-5. Pt-concentration in each tissue at 2, 24, and 48 h after intravenous 
injection of 4Pt(dach)ClTPyP (n = 3; (Bld = blood; Spl = spleen; Pan = 
pancreas; Sto = stomach; L-Int = large intestine; S-Int = small intestine; Kid = 





























3.3.7 In vivo PDT on subcutaneous tumor-bearing mice 
Further experiments were performed to evaluate the therapeutic effect of 
4Pt(dach)ClTPyP toward Colon26 tumor-bearing mice by monitoring the tumor 
volume. Mice in group 1 were intravenously injected with 4Pt(dach)ClTPyP 
and mice in group 2 were not administrated as control. Each mouse in these two 
groups underwent irradiation on a tumor located on the left shoulder and no 
irradiation on the right shoulder. To assess the side effects, the body weight was 
also measured. As indicated in Fig. 3-6 and Fig. 3-7a, the tumor on both 
shoulders of group 2 and on the right shoulder of group 1 were not inhibited 
and showed similar growth speeds. When comparing the tumor volumes of 
group 2, there was no significant difference between the left shoulder and right 
shoulder, suggesting that light irradiation only does not affect tumor growth. 
No obvious difference was found between the tumor on right shoulders of both 
groups, hence, dark cytotoxicity of 4Pt(dach)ClTPyP is insignificant; however, 
the left tumor in group 1 disappeared on day 4 after 4Pt(dach)ClTPyP-mediated 
PDT and remained absent for 18 days (P < 0.05 vs. the right tumor volume). 
Therefore, this complex has been demonstrated to completely killed tumor cells, 
rather than inhibiting tumor growth. In the treated group, body weight 
measurements showed that the mice had no appreciable weight loss (less than 
6%, Fig. 3-7b). Skin damage was detected after administration, but recovered 
with time (Fig. 3-6). All of the results indicate that 4Pt(dach)ClTPyP is capable 
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of tumor removal in Colon26 tumor-bearing mice and could be an effective 




Fig. 3-6. BALB/c mice bearing Colon26 cancer cells before photoirradiation 
(1a and 2a), 6 days (1b and 2b), and 18 days (3a and 3a) after PDT treatment of 
4Pt(dach)ClTPyP. The mouse in 1a, 1b, and 1c was in Group 1, and the mouse 





Fig. 3-7. In vivo PDT evaluation of 4Pt(dach)ClTPyP in Conlon26 
tumor-bearing mice. (a) Tumor growth curves of group 1 (4Pt(dach)ClTPyP, n 
= 4) and group 2 (Control, n = 4). The tumor volumes were normalized to their 
initial sizes. (b) Relative weight of group 1 and group 2. The error bars 
represent the standard deviations of 4 mice per group. *, p < 0.05; **, p < 0.01, 
***, p < 0.001
 79 
3.4 Conclusions 
In summary, to obtain a potential photosensitizing agent with high antitumor 
effect, a porphyrin framework as a carrier to tumor tissue and a Pt (II)-based 
chemotherapeutic drug were combined and characterized. The positive 
charge-rich regions of this complex prohibit formation of aggregates by 
electrostatic repulsion and facilitate metal-to-ligand charge transition to 
increase singlet oxygen quantum. The synthesized complex, 4Pt(dach)ClTPyP, 
showed negligible dark toxicity and excellent photocytotoxic properties through 
high singlet oxygen and apoptosis mechanisms. We speculated the mechanism 
of its anticancer activity in Fig. 3-8. In vivo PDT efficacy of this complex was 
conducted using Colon26 tumor-bearing mice via tail vein injection. This 
complex accumulated in the tumors, demonstrating splendid photodynamic 
cancer killing efficacy over two weeks in an in vivo PDT assay. Based on these 











In this study, to obtain potential photosensitizing anticancer agents with improved 
hydrophilicity and high tumor accumulation, a porphyrin framework, Pt(II)-based 
chemotherapeutic drug, and metal ions were combined and their photophysical and 
photochemical properties were investigated. Anticancer activity and the mechanism 
were further studied in vitro and in vivo.  
 
1. Water-soluble metalloporphyrinates with excellent photo-induced anticancer 
activity resulting from high tumor accumulation 
• Two pentacationic gallium porphyrinates Ga-4cisPtPyP and Ga-4transPtPyP 
were synthesized. 
• Compared with metal-free porphyrinate 4cisPtTPyP, Ga-4cisPtPyP is an 
efficient singlet oxygen generator because of heavy atom effect, more acidic 
pKa, and localization in cytosol. 
• It also showed negative dark cytotoxicity caused by more hydrophilicity and 
slower and lower cellular uptake. 
• Ga-4cisPtTPyP exhibited excellent photocytotoxic activity both in vitro and 
in vivo.  
• The excellent photocytotoxicity, interaction with DNA, and apoptosis 
pathway could contribute to the anticancer activity of Ga-4cisPtPyP. 
• Ga-4cisPtTPyP displayed high tumor accumulation. 
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2. Effect of metalation on water-soluble cationic metalloporphyrins in photodynamic 
therapy 
• Four cationic porphyrinates Zn-4cisPtPyP, Zn-4transPtPyP, In-4cisPtPyP and 
In-4transPtPyP were synthesized. 
• These complexes showed high singlet oxygen quantum yields due to heavy 
atom effect.  
• In-4cisPtTPyP exhibited excellent photocytotoxic activity both in vitro and in 
vivo.  
 
3. A platinum-porphyrin conjugate: an excellent cancer killer for photodynamic 
therapy 
• The synthesized complex, 4Pt(dach)ClTPyP, showed negligible dark toxicity 
and excellent photocytotoxic properties. 
• The mechanism of its anticancer activity was speculated on high singlet 
oxygen and apoptosis pathway. 
• 4Pt(dach)ClTPyP completely killed tumor cells, not simply displaying 
inhibition of tumor growth.  
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